|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, genetic or pharmacologic targeting of cyclin-D1 combined with a proapoptotic BH3 mimetic synergistically killed the cyclin-D1-expressing murine lymphomas, human MCL cell lines, and primary lymphoma cells.
|
21746927 |
2011 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
As cyclin D1 overexpression is a common phenomenon in different cancers, BCL-6 protein overexpression may not be restricted to lymphomas.
|
14654791 |
2003 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
In human blood cancers, loss of Rb expression has been widely reported in both acute myeloblastic and acute lymphoblastic leukemias, cyclin D1 amplification is common in mantle cell lymphoma, and silencing of the p16/INK4a tumor suppressor gene occurs frequently in AML and various types of lymphoma.
|
15611658 |
2005 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemical expression of PRAD1/cyclin D1 protein has been investigated in 106 tissue specimens of 104 cases of lymphoma, non-neoplastic lymphoid disorders and other hematologic malignancies by employing the monoclonal antibody 5D4 with formalin-fixed paraffin-embedded sections, using the microwave oven heating method.
|
7531681 |
1994 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Aberrant Cyclin D1 expression seems to promote proliferation in other types of lymphoma, while a growth promoting CCND1/TACSD1(TROP2) fusion product has also been described in tumors.
|
19554511 |
2009 |
|
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Three of the seven centrocytic lymphomas had detectable BCL1 DNA rearrangement.
|
1682919 |
1991 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Lymphoma cell lines harboring the t(11;14) showed cyclin D1 protein but no or very low levels of cyclin D3; three other B-cell lines, a T-cell line, and peripheral blood lymphocytes strongly expressed cyclin D3 and reacted negatively for cyclin D1.
|
9376597 |
1997 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
PRAD1 (previously D11S287) is a putative proto-oncogene at 11q13, activated by overexpression through gene rearrangement or gene amplification in several types of human tumors including parathyroid adenomas, centrocytic lymphomas and other B-cell tumors with t(11;14), and breast cancers.
|
7687458 |
1993 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In parallel, we investigated the relationship between p27(Kip1), the lymphoma proliferation index, Epstein-Barr virus status, expression of cellular cyclin D3 and cyclin D1, and B-cell differentiation stage.
|
12107101 |
2002 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Cyclin D1 overexpression was found in 60/61 MCLs and in none of the other lymphomas, except for 12/19 mucosa-associated lymphoid tissue lymphomas from the lungs and stomach, which also revealed cyclin D1 overexpression.
|
18303407 |
2008 |
|
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Rearrangements at the chromosome 11q13 bcl-1 breakpoint loci are present in the majority of these lymphomas, as a result of reciprocal translocation with the 14q32 immunoglobulin heavy chain joining genes.
|
8426477 |
1993 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, a significant proportion of translocation breakpoints in band 11q13 may not be detected by the BCL1 MTC probe in MM, as is true in lymphomas.
|
1415486 |
1992 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The mRNA and protein expression levels of B cell leukemia/lymphoma (Bcl‑2), Bcl‑2 associated X (Bax), cyclin dependent kinase 4 (CDK4), cyclin D1 and p21 were evaluated using reverse transcription‑polymerase chain reaction and western blot analysis, respectively.
|
29115462 |
2018 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our results show that cyclin-D2 and D3 proteins are expressed in many more lymphoma subtypes than cyclin-D1.
|
20062012 |
2010 |
|
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Mantle cell lymphoma (MCL) is a distinct subtype of malignant lymphoma which is characterized by the chromosomal translocation t(11;14)(q13;q32) resulting in constitutional overexpression of cyclin D1 and cell cycle dysregulation in almost all cases.
|
25015778 |
2015 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Cyclin D1-positive large B-cell lymphoma is rare, but as large B-cell lymphoma is a common type of lymphoma, cyclin D1-positive large B-cell lymphoma should be considered a major possibility during differential diagnosis, including in the tonsils.
|
28296741 |
2017 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In particular, the recognition of chromosomal translocations which have activated the BCL1 and BCL2 proto-oncogenes have strong associations with specific types of non-Hodgkin's malignant lymphomas such as mantle cell lymphoma and follicular center cell lymphoma, respectively.
|
8852399 |
1995 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We examined 151 cases of lymphoma with MCL morphology from a viewpoint of cyclin D1 overexpression, which is now easily detectable by immunohistochemistry.
|
10733493 |
2000 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Statistical analysis of the expression data revealed the combination of CCND1 and CDK4 as the best classifier concerning separation of both lymphoma types.
|
12036888 |
2002 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We implemented a system based on this specificity to investigate the mechanism of BCL1 lymphoma protection induced by DNA immunisation.
|
15692846 |
2005 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Among the 23 validated genes were cyclin D1 (CCND1) and B-cell CLL/lymphoma 2, which have well-known roles in lymphoma pathogenesis.
|
14961037 |
2004 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, in transgenic mice, the overexpression of cyclin D1 alone is not sufficient for the development of malignant lymphoma.
|
9377576 |
1997 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The contribution of other chromosomal abnormalities other than bcl-1 and bcl-2 rearrangements in the pathogenesis of MCL and follicular-cell lymphomas has to be determined.
|
10319386 |
1999 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The latter parameters and IPI were the only ones with independent prognostic value (RR = 10, 5.0, 6.7, and 3.7, respectively; P < 0.001) when assessed together with lymphoma sub-type, primary versus relapse cases, treatment, B symptoms, S phase fraction, and presence of BCL1 and BCL2 translocations.
|
11747333 |
2001 |
|
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Accordingly, this isotype was the most effective in eradicating BCL1 lymphoma but had limited efficacy in s.c. tumors.
|
29109120 |
2017 |